ENLV Stock Overview
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Enlivex Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.40 |
| 52 Week High | US$4.59 |
| 52 Week Low | US$1.15 |
| Beta | 1.06 |
| 1 Month Change | -65.60% |
| 3 Month Change | -48.91% |
| 1 Year Change | -52.38% |
| 3 Year Change | -85.90% |
| 5 Year Change | -84.42% |
| Change since IPO | -86.41% |
Recent News & Updates
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
Apr 04
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Dec 13Recent updates
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
Apr 04Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Dec 13Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
Jul 25Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Apr 05Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Nov 16Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Sep 30Enlivex to gets US patent covering use of cell therapy Allocetra
Sep 06Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Aug 29Envilex Therapeutics reports Q2 results
Aug 22We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Jul 08Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment
Jul 06We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Mar 23Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Nov 25We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
Aug 12Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy
Jun 15Enlivex issued new Canadian patent for Allocetra immunotherapy
Jun 01We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn
Apr 29Enlivex shares rise 20% on positive Allocetra data in COVID-19
Feb 03Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Jan 11
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?
Nov 19Shareholder Returns
| ENLV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.5% | -4.7% | -3.7% |
| 1Y | -52.4% | -2.7% | 20.2% |
Return vs Industry: ENLV underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: ENLV underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| ENLV volatility | |
|---|---|
| ENLV Average Weekly Movement | 21.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ENLV's share price has been volatile over the past 3 months.
Volatility Over Time: ENLV's weekly volatility has increased from 15% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Oren Hershkovitz | www.enlivex.com |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors.
Enlivex Therapeutics Ltd. Fundamentals Summary
| ENLV fundamental statistics | |
|---|---|
| Market cap | US$26.04m |
| Earnings (TTM) | -US$29.07m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs ENLV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENLV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.07m |
| Earnings | -US$29.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ENLV perform over the long term?
See historical performance and comparison